百脉根苷 | 534-67-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 百脉根苷
• 英文名称: (1R)-1-Cyano-1-methylpropyl-β-D-glucopyranoside
• 英文别名: lotaustralin；(R)-2-β-D-glucopyranosyloxy-2-methyl-butyronitrile；(R)-2-β-D-Glucopyranosyloxy-2-methyl-butyronitril；(2R)-2-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanenitrile
• CAS: 534-67-8
• 化学式: C₁₁H₁₉NO₆
• 分子量: 261.275
• InChiKey: WEWBWVMTOYUPHH-QHAQEBJBSA-N

物化性质

• 熔点：
  106 - 109°C
• 溶解度：
  DMSO（轻微）、甲醇（轻微）、水（轻微、加热、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  123
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  百脉根苷 、 乙酸酐 生成 [(2R,3R,4S,5R,6S)-3,4,5-triacetyloxy-6-[(2R)-2-cyanobutan-2-yl]oxyoxan-2-yl]methyl acetate
  参考文献：
  名称：

  JAROSZEWSKI, JERZU W.;SKJZHUSTOTTGAARD, JENSEN PIA;CORNETT, CLAUS;BYBERG,+, BIOCHEM. SYST. AND ECOL., 16,(1988) N 1, 23-28

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲醇 、 barium methoxide 作用下， 生成 百脉根苷
  参考文献：
  名称：

  Cyanogenesis in manioc: Concerning lotaustralin

  摘要：

  DOI：

  10.1016/s0031-9422(00)88188-1

文献信息

• [EN] HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES<br/>[FR] ANTICORPS ANTI-TN-MUC1 HUMANISÉS ET LEURS CONJUGUÉS
  申请人：CANCER REC TECH LTD

  公开号：WO2015159076A1

  公开（公告）日：2015-10-22

  Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.

  人性化抗Tn-MUC1抗体及其结合物。描述了包含吡咯苯并二氮杂环己烷（PBDs）的结合物，其具有作为连接物的不稳定保护基团。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• [EN] METHOD AND MOLECULES<br/>[FR] MÉTHODE ET MOLÉCULES
  申请人：MEDIMMUNE LLC

  公开号：WO2018218093A1

  公开（公告）日：2018-11-29

  The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.

  本发明提供了一种生物共轭方法和其中使用的化合物。该生物共轭方法包括将含有第一不饱和官能团的生物分子与包含第二不饱和官能团的荷载物质共轭的步骤，其中第一和第二不饱和官能团互补，使得通过 Diels-Alder 反应发生官能团之间的结合，形成一个环己烯环。
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT SITE-SPÉCIFIQUES
  申请人：VAN BERKEL PATRICIUS HENDRIKUS CORNELIS

  公开号：WO2016166299A1

  公开（公告）日：2016-10-20

  Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.

  特定于位点的抗体药物偶联物被描述，特别是包括结合PSMA的抗体的偶联物，其包括通过将链间半胱氨酸残基替换为非半胱氨酸和具有易裂解保护基的吡咯并苯二氮䓬啉（PBDs）的氨基酸的偶联物。偶联位置以及抗体部分的修饰，可以提高ADC的安全性和有效性。
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT SPÉCIFIQUES À UN SITE
  申请人：VAN BERKEL PATRICIUS HENDRIKUS CORNELIS

  公开号：WO2016166341A1

  公开（公告）日：2016-10-20

  Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds CD25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

  描述了特定于位点的抗体药物共轭物，特别是包括一种抗体的共轭物，该抗体结合CD25并包括通过氨基酸替换使一个链间半胱氨酸残基成为非半胱氨酸的氨基酸，以及具有以连接物形式的易降解保护基团的吡咯苯并二氮杂环己烯酮（PBDs）。结合位点以及抗体部分的修饰，可提高ADC的安全性和有效性。